Halozyme 2022 Corporate Presentation | ENHANZE Drug Delivery Platform

Halozyme is a profitable biopharma company presenting its ENHANZE® drug delivery platform and autoinjector device technology. The presentation covers the company's diversified revenue streams, commercially validated portfolio, and 2022 financial guidance of $655-685 million, representing 48-55% growth year-over-year.